Actively Recruiting
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
Led by University of Rochester · Updated on 2025-09-08
48
Participants Needed
1
Research Sites
246 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.
CONDITIONS
Official Title
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologic diagnosis of Non-Small Cell Lung Cancer (NSCLC) without targetable/oncogene driven mutations (EGFR, ALK, ROS1).
- Stage IV disease (T1-4N0-3M1a-c) or metastatic recurrence of primary Stage I-III NSCLC treated with curative intent, without prior thoracic radiotherapy.
- Thoracic lung and/or nodal lesions suitable for palliative chest radiotherapy.
- Presence of high-risk features: a non-central primary lung lesion ≥5 cm; or bulky (≥2 cm) parenchymal lung or nodal lesions near critical chest structures.
- Prior systemic therapy allowed; must enroll within 6 months of first systemic therapy cycle for Stage IV disease.
- Systemic therapy following thoracic radiotherapy allowed.
- Prior palliative surgical treatments allowed.
- Concurrent chemotherapy within 2 days before to 2 days after radiotherapy is not allowed.
- Concurrent immunotherapy allowed.
- Standard extrathoracic radiotherapy allowed off protocol.
- Concurrent palliative thoracic radiotherapy and radiotherapy for thoracic bone metastases allowed.
You will not qualify if you...
- Prior radiation therapy to the thoracic region.
- Active systemic lupus or Sjogren's disease.
- Severe symptoms from NSCLC requiring urgent thoracic palliative radiotherapy for conditions other than bone pain (e.g., superior vena cava syndrome, large volume hemoptysis, airway obstruction, spinal cord compression).
- Baseline ECOG performance status of 3 or 4.
- Brain metastases not treatable by immunotherapy alone, surgery, or stereotactic radiosurgery.
- Malignant pleural effusion caused by visible pleural disease; patients with effusion manageable by thoracentesis without pleural masses may be eligible.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Rochester
Rochester, New York, United States, 14642
Actively Recruiting
Research Team
T
Therese Smudzin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here